Gastrointestinal OTC Drugs Market to grow with a CAGR of 3.80%
Increasing healthcare infrastructure and
a supportive regulatory environment are the major drivers for the Global Gastrointestinal
OTC Drugs Market.
According
to TechSci Research report, “Global Gastrointestinal OTC Drugs Market Industry
Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028”, Global Gastrointestinal OTC
Drugs Market has valued at USD 31 billion in 2022 and is anticipated to witness
an impressive growth in the forecast period with a CAGR of 3.80% through 2028. This can be due to collaborations and
partnerships among leading companies with a diverse approach to merge the
expertise of individual companies and to strengthen their position in the
market.
The increasing prevalence of gastrointestinal
disorders is a significant driver of demand in the global gastrointestinal over
the counter (OTC) drugs market. Gastrointestinal disorders, including
conditions like acid reflux, irritable bowel syndrome (IBS), constipation, and
diarrhea, are becoming more prevalent worldwide. This can be attributed to
factors such as changes in dietary habits, lifestyle choices, and stress
levels. Modern diets often include processed foods, high-fat content, and
excessive sugar, which can lead to digestive problems. Diets low in fiber can
contribute to constipation, while high-fat diets may increase the risk of acid
reflux and indigestion. High-stress levels, irregular eating patterns, lack of
physical activity, and sedentary lifestyles can disrupt digestive health and
contribute to gastrointestinal issues. Stress has been linked to conditions
like irritable bowel syndrome. The trend of self-care and self-medication is on
the rise. Many consumers prefer to address common gastrointestinal symptoms
with OTC drugs before seeking medical attention, further boosting demand for
these products. Dietary preferences are evolving globally, with an increasing
emphasis on gut health and digestive wellness. Consumers are more likely to
explore OTC options to support and maintain their gastrointestinal health. Chronic
gastrointestinal conditions, such as gastroesophageal reflux disease (GERD),
Crohn's disease, and ulcerative colitis, require ongoing management. Patients
often use OTC drugs as part of their long-term treatment plans.
Browse
over XX market data Figures and spread through XX Pages and an in-depth TOC on
" Global Gastrointestinal OTC Drugs Market.”
Anyone
may buy gastrointestinal OTC products as they do not require a prescription
from a doctor. Over the counter (OTC) medications are widely used to treat
minor gastrointestinal issues worldwide, where half of the population suffers
from various gastrointestinal disorders. Additionally, OTC medications are the
first line of defense in the fight against any gastrointestinal illnesses or
diseases, including GERD and heartburn.
In
May 2020, As the first brand-new medication expressly authorized as a fourth-line
therapy for advanced gastrointestinal stromal tumor (GIST), a form of tumor
that develops in the digestive system, the U.S. Food and Drug Administration
approved Qinlock (ripretinib) tablets. Adult patients who have already
undergone therapy with three or more kinase inhibitor treatments, including
imatinib, are eligible for Qinlock. The FDA authorized Qinlock based on the
findings of an international, multi-center, randomized, double-blind,
placebo-controlled clinical study that included 129 patients with advanced GIST
who had previously been treated with imatinib, sunitinib, and regorafenib,
three additional FDA-licensed targeted treatments. To ascertain whether
progression free survival (PFS), which measures the amount of time between the
start of treatment in a clinical trial and the growth of the cancer or death,
was longer in the Qinlock group than the placebo group, the trial compared
patients who were randomly assigned to receive Qinlock to patients who were
randomly assigned to receive a placebo.
Side
effects and the potential for dependency can be challenges in the global
gastrointestinal over the counter (OTC) drugs market, as they are for many
types of medications, both prescription and OTC. Some gastrointestinal OTC
drugs, such as antacids, laxatives, and anti-diarrheal medications, may cause
side effects related to the gastrointestinal tract itself. For example,
laxatives can lead to cramping, diarrhea, or dehydration, while antacids may
cause constipation. In certain cases, OTC drugs intended for gastrointestinal
relief can have systemic side effects. For example, long-term or excessive use
of proton pump inhibitors (PPIs) used to treat heartburn may lead to nutrient
deficiencies, kidney issues, or an increased risk of bone fractures. Allergic
reactions to certain ingredients in OTC drugs, such as artificial colors,
flavorings, or inactive ingredients, can occur and range from mild skin rashes
to severe anaphylactic reactions.
Global Gastrointestinal OTC Drugs Market segmentation
is based on
Drug Class, Indication, End-User, and
Region.
Based on Drug
Class, Global Gastrointestinal OTC Drugs Market is segmented into Laxatives,
Gastrointestinal Cancer Treatments, Gastric Acid Reducers, Anti-Diarrheal,
Proton Pump Inhibitors, H2 Inhibitors, Gastric Acid Neutralizers, Bowel
Anti-Inflammatory, Anti-Emetics. Bowel anti-inflammatory typically
refers to treatments or medications that are designed to reduce inflammation in
the bowel, specifically in conditions that affect the digestive tract. These
conditions often involve chronic inflammation, which can lead to a range of
gastrointestinal symptoms and potential complications. The primary goal of
bowel anti-inflammatory treatments is to reduce inflammation in the bowel and
induce a period of remission, where symptoms are minimal or absent. Drugs like
azathioprine, mercaptopurine, and methotrexate are used to suppress the immune
system's response, which can help control inflammation in the digestive tract.
They are often used in cases of moderate to severe IBD when other treatments
are ineffective.
Based on Region, North America dominated the Global Gastrointestinal OTC Drugs Market. The
region has well-established retail distribution channels, including pharmacies,
drug stores, and supermarkets, where consumers can easily access OTC
gastrointestinal drugs. These retail outlets often carry a wide range of OTC
medications, including those for digestive health. While many OTC drugs are
purchased without a prescription, some are covered by health insurance plans in
North America. This can reduce the out-of-pocket costs for consumers, making
OTC medications more accessible. In North America, consumers can often consult
with pharmacists for guidance on OTC drug selection. This accessibility to
healthcare professionals can influence consumers to choose OTC gastrointestinal
drugs for their digestive issues. Pharmaceutical companies in North America
invest heavily in marketing and advertising campaigns to promote their OTC
gastrointestinal products. These efforts create consumer awareness and
influence purchasing decisions.
Asia-pacific region to witness fastest growth in the
Global Gastrointestinal OTC Drugs Market.
The Asia-Pacific region is home to a large and rapidly growing population. As
more people migrate to urban areas, there is increased exposure to factors like
stress, dietary changes, and sedentary lifestyles, which can lead to
gastrointestinal issues. This demographic shift contributes to a higher demand
for gastrointestinal OTC drugs. Economic development in many Asia-Pacific
countries has led to changes in lifestyle and dietary habits. People are
consuming more processed and fast foods, which can contribute to digestive
problems, including heartburn and indigestion. This dietary shift boosts the
need for OTC remedies. Growing awareness of health and wellness, along with
access to information through the internet and social media, has led consumers
in the Asia-Pacific region to be more proactive about addressing their health
concerns, including digestive issues. This drives the demand for OTC drugs as
consumers seek self-care options.
Some
of the major companies operating in the Global
Gastrointestinal OTC Drugs Market include:
- Teva Pharmaceuticals Industries Ltd
- Mylan
N.V
- Sandoz
AG
- Johnson
& Johnson Services, Inc.
- Sun
Pharmaceuticals Industries Limited
- Teva
Pharmaceuticals Industries Ltd.
- Zydus
Life Science Ltd.
- Sanofi
SA
- Bayer AG
- Pfizer Inc.
- GlaxoSmithKline Plc.
Download
Free Sample Report
Customers can also request for 10% free
customization on this report.
“Certain areas, particularly in North
America, are projected to exert significant demand for Gastrointestinal OTC
Drugs. The growth in the competitive landscape and the presence of
well-established companies in the market, committed to enhance the overall
wellbeing of people each year, are expected to contribute to a remarkable
growth of the Global Gastrointestinal OTC Drugs Market in the forecast period,"
said Mr. Karan Chechi, Research Director with TechSci Research, a
research-based Global management consulting firm.
Gastrointestinal OTC Drugs Market – Global Industry Size, Share,
Trends, Opportunity, and Forecast, 2018-2028 Segmented by Drug Class (Laxatives,
Gastrointestinal Cancer Treatments, Gastric Acid Reducers, Anti-Diarrheal,
Proton Pump Inhibitors, H2 Inhibitors, Gastric Acid Neutralizers, Bowel Anti-Inflammatory, Anti-Emetics), By Indication
(Gastroesophageal Reflux Disease or Heartburn, Constipation, Diarrhea, Motion
Sickness, and Others), By End User (Hospitals Pharmacies, Retail Pharmacies, Online
pharmacies, others), by region, and Competition evaluated
the future growth potential of Global Gastrointestinal OTC Drugs Market and
provides statistics & information on market size, structure, and future
market growth. The report intends to provide innovative market intelligence and
help decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Gastrointestinal OTC Drugs Market.
Contact
Mr.
Ken Mathews
708
Third Avenue,
Manhattan,
NY,
New
York 10017
Tel:
+1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com